FL-EIGHT-SLEEP
18.3.2022 17:02:08 CET | Business Wire | Press release
Eight Sleep , the world's first sleep fitness company, today announced that the Mercedes-AMG Petronas Formula 1 Team has named the company as Official Team Supplier in a joint effort to support the team’s preparations for an expansive 2022 Formula 1 schedule. The Mercedes-AMG Petronas team including drivers, Lewis Hamilton, George Russell, as well as Team Principal, Toto Wolff, will have access to Eight Sleep’s suite of products to optimize their sleep and ensure peak performance this and next season.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220318005290/en/
The Mercedes-AMG Petronas F1 Team rigorously looks for ways to improve the performance of the car and the team. Eight Sleep’s next-generation sleep technology is engineered to support the technical and human demands of the intense 2022 F1 schedule, enabling the 8x Champions to maintain their long term success. The Mercedes-AMG Petronas F1 Team joins Eight Sleep along with more than 200 professional athletes who rely on Eight Sleep to power their recovery through the Pod Pro’s advanced thermoregulation and sleep technology.
In addition to Eight Sleep’s branding being featured on the team’s car for the inaugural Miami Grand Prix, the Eight Sleep logo will be featured on all the car covers for the duration of the season. Eight Sleep will support Mercedes-AMG Petronas F1 team members to power their performance through their innovative sleep technology Data has shown that Eight Sleep products help 49% of Eight Sleep members see an increase in their HRV of at least 10% one week after sleeping on the Pod.
With grueling schedules that consist of training, racing, and traveling, it’s critical that team members properly refuel and recover in order to perform their best. When they are pushing their bodies to their limits, in between the training, racing and hectic traveling schedules, the team needs to properly recover and refuel. Eight Sleep’s thermoregulation is designed to recharge the team to peak energy levels, which will be critical for the Mercedes-AMG Petronas Formula One Team in 2022. Additionally, the Eight Sleep App leverages the product’s sensor technology to provide daily reports on key health metrics, such as heart rate, HRV, sleeping stages, and more, giving the team the ability to build better health regimes and optimize their sleep.
“Our team is made up of over 2,000 people across Brackley and Brixworth, all of whom perform at their peak every day in a sport where every single detail matters. To achieve the level of sustained performance that is required to compete in Formula 1, we are relentless in exploring all possible optimizations, including sleep. By partnering with Eight Sleep we are looking to utilize their technology during the upcoming season while also spreading a key message about the importance of recovery when you aim for peak performance,” said Toto Wolff, Team Principal and CEO of the Mercedes-AMG Petronas F1 Team.
“Eight Sleep, and myself personally, are thrilled to partner with Mercedes-AMG Petronas Formula One and power their team’s sleep so they can continue to perform at the highest level,” said Matteo Franceschetti, Co-Founder and CEO of Eight Sleep. “Growing up in Italy, Formula One was a huge part of my life – from racing cars with my father to starting my first business taking pictures of racing cars at local tracks. Mercedes-AMG Petronas F1’s commitment to constant innovation and improvement is what we strive for at Eight Sleep. We will work together to improve the team’s sleep and recovery for a successful win at this year’s Grand Prix races.”
“We’re delighted to welcome Eight Sleep to the team and to start working with them to develop and innovate around our sleep and recovery programmes,” said Richard Sanders, Commercial Director of the Mercedes-AMG Petronas F1 Team. “Eight Sleep’s approach to reimagining sleep is very similar to how we operate. They’re obsessed with performance, the fine details and ensuring our team gets the rest they need to perform at their very best.”
The Pod Pro by Eight Sleep
The Pod Pro by Eight Sleep is the most advanced solution on the market for thermoregulation. The Pod Pro retains vital features of the original and award-winning Pod, introducing new Room Climate and Weather Response, a Comfort Blend™ Integrated Topper, GentleRise™ Wake Up Technology, and double the amount of sensors enabling new Heart Rate Variability monitoring and a Daily Health Check report. The advancements in the Pod Pro help everyone with their rest and recovery – from elite athletes to everyday consumers. The product transforms any ordinary bed into an advanced health platform that fuels both performance and longevity.
Current and former Eight Sleep athletes include Red Gerard (2018 Gold Medalist, Snowboarding), Brooke Wells (Two-time individual CrossFit Gamesathlete), Apolo Ohno (Two-Time Gold Medalist, Speed Skating), Justin Medeiros (CrossFit Champion 2021), Daniel Sturridge (English Soccer Player), Daryl Homer (2020, and 2016 Silver Medalist, Fencing), and Jane Campbell (2020 Bronze Medalist, Soccer). Eight Sleep’s athlete-investors include Alex Rodriguez (retired MLB athlete and entrepreneur), Matthew Dellavedova (2020 Bronze Medalist, Basketball), Kris Bryant (San Francisco Giants outfielder), and J.D. Martinez (Boston Red Sox outfielder).
About Eight Sleep
Eight Sleep is the world's first sleep fitness company with a mission to fuel human potential through optimal sleep. Eight Sleep leverages thermoregulation, data, and technology to restore individuals to their peak energy levels every morning. Eight Sleep was named one of Fast Company's “Most Innovative Companies of 2022” and “Most Innovative Companies of 2018,” and recognized two years in a row by TIME's “Best Inventions of the Year.” To learn more, visit eightsleep.com .
About Mercedes-AMG Petronas Formula One
Mercedes-AMG Petronas Formula One Team is the works team of Mercedes-Benz, competing at the pinnacle of motorsport – the FIA Formula One™ World Championship.
Formula One is like nothing else in the sporting sphere. It’s a demanding technical and human challenge, combining cutting-edge technologies and innovation, high-performance management and elite teamwork.
At Mercedes-AMG Petronas Formula One Team, a group of passionate and determined people work to design, develop, manufacture and race the cars driven by seven-time World Champion Lewis Hamilton and young star George Russell.
The team has set a new benchmark for F1 success during the sport’s current Hybrid era, winning consecutive Drivers’ and Constructors’ World Championships in 2014, 2015, 2016, 2017, 2018, 2019 and 2020, and the Constructors’ Championship in 2021. During those title-winning seasons, the team has scored 111 wins, 232 podium finishes, 118 pole positions, 81 fastest laps and 53 one-two finishes from 160 race starts.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220318005290/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom